The Global Fund
To Fight AIDS, Tuberculosis and Malaria

# LIST OF ARV PHARMACEUTICAL PRODUCTS
## classified according to the Global Fund Quality Assurance Policy

**Edition: Version 118**
**March 2015**

The list is an overview of pharmaceutical products subject to the Global Fund Quality Assurance Policy that are listed in National and/or WHO standard treatment guidelines and classified according to the various options (A, B, and ERP reviewed) defined in the Global Fund Quality Assurance Policy (July 2009, amended in December 2010). The list is developed as a tool to assist Principal Recipients (PR) of Global Fund grants to identify the status of finished pharmaceutical products according to the Global Fund Quality Assurance Policy.

The pharmaceutical products are classified based on the following information

**A** classified product - Listed on WHO prequalification list;
**B** classified product - Stringent NDRA Registration letter/Marketing Authorization;
**ERP reviewed** product- **Permitted for time-limited procurement** based on advice by the Expert Review Panel (ERP);

**Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the current list as long as PR demonstrates that the product is compliant with the Global Fund Quality Assurance Policy.**

The Global Fund list includes the following information:

- "**Important Notes"** for helpful information;
- **A, B, and ERP** reviewed products;
- Period **validity** of the ERP reviewed products;
- **"+"** means combination product, both fixed-dose combination (co-formulated) and co-packaged product ( i.e. co-blister)
- **[A+B]+C** means A and B are in fixed-dose formulation and C is co-packaged

YELLOW signifies a new entry; PINK signifies modification of an existing entry.

**For more information, please look at:**
**http://www.theglobalfund.org/en/about/procurement/list/**

**Expert Review Panel (ERP):** Expert Review Panel is an independent technical body composed of external technical experts, hosted by WHO Department of Essential Medicines and Pharmaceutical Policies, to review the potential risks/benefits associated with the use of FPPs that are not yet WHO-prequalified or SRA-authorized and to advise the Global Fund in its decision on whether to allow grant funds to be used to procure FPP. ERP reviewed products can be procured for a limited time (maximum 12 months). However, under certain circumstances, it is possible to extend the recommendation period. Contracts to supplier/manufacturer for an ERP reviewed products should not be longer than the validity period of the recommendation of that product. For detail information on ERP process and Quality Assurance information, please look at **http://www.theglobalfund.org/en/procurement/quality/?lang=en**

**Procurement of ERP Reviewed Products:** Principal Recipients (PRs) must inform the concerned Fund Portfolio Manager (FPM) at the Global Fund in writing by filling the **"Notification Form"** ( available on website) if they intend to procure
ERP-reviewed product(s). The Global Fund Secretariat will review the notification request and upon issuing a " no objection" letter to the PR for the requested selection, procurement can only proceed.

## Important Notes

This List may be used by Principal Recipients of Global Fund grants when considering options with respect to procurement of pharmaceutical products pharmaceutical products subject to the Global Fund Quality Assurance Policy. The list aims at providing countries with information that will assist them in their procurement options. Please note that the list is not designed to be a basis for countries to select medicines to be included in their National Treatment Guidelines or to replace any applicable and legally required procurement processes. The Global Fund requires its grant recipients to comply with applicable procurement laws and provides the list only for the **identification of products/manufacturers that comply with the Global Fund's quality assurance policy**. It is important to note that there is no strict requirement to procure according to the list, as long as the Principal Recipients can ensure that the product selected is compliant with the Quality Assurance policy criteria. Furthermore, the Principal Recipient should not rely solely on the information provided in the list but should obtain evidence of products compliance with the Quality Assurance policy. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

**The Lists will be updated regularly based on evidence received by the Global Fund. Interested parties are invited to supply information** and evidence of products meeting the policy criteria on an ongoing basis. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

**According to the Global Fund QA policy, if there are two or more A or B classified manufacturers available for any given product AND the product is available from these manufacturers (available-means that the manufacturer can supply the selected product within 90 days after receiving the Purchase Order), then such product must be procured from A or B classified product manufacturers. The PR must notify by writing to the Global Fund Secretariat (Fund Portfolio Manager) and recieve the "No Objection" letter from GF secretariat before procuring any products complying with option " ERP Reviewed".**

**For ease of reference, each "product" has been identified in this list with a unique "Product reference number" (Column A). Please see examples below.**

Several different dosage forms may be grouped under the same Product Reference Number and therefore will be considered the same type of products when identifying the number of available manufacturers for the application of this policy. These products share the same dosing protocol, target the same population, and there are no fundamental differences among them. For example, within solid forms, some capsules will have same reference number as tablets while within liquids, oral solution and suspension are grouped together.Similarly, the entero coated tablet or dispersible tablet will not share the same reference number as non entero coated or dispersible tablets.

| Product Ref.No | International Non-proprietary name | Strength | Dosage form | Supplier/Manufacturer | Global Fund QA Standard | WHO Pre-qualified/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **16** | **XYZ** | **50mg** | Tablet | "Pharma Company A" | A - B | Yes | "Pharmaville" | Country A | HDPE bottle | 60 |
| **17** | | **100mg** | Tablet | "Pharma Company B" | A - B | Yes | "Pharmaville" | Country B | HDPE bottle | 60 |

The example above shows 2 different variants of the same medicine. Because the strength is different, it is considered 2 different products (there are two different reference numbers 16 and 17). If the strength had been the same but the dosage form had been different (i.e. tablet and liquid) it would also have been considered two different "products".

| Product Ref.No | International Non-proprietary name | Strength | Dosage form | Supplier/Manufacturer | Global Fund QA Standard | WHO Pre-qualified/ SRA | Manufacturing site | Country | Packaging | |
|---|---|---|---|---|---|---|---|---|---|---|
| **25** | **ABC** | **150mg** | Tablet | "Pharma Company A" | A - B | Yes | "Pharmaville" | Country A | Blister, HDPE bottle | 10, 60 |
| | | | Capsules | "Pharma Company B" | A - B | Yes | "Pharmaville" | Country B | HDPE Bottle, | 60, 10 |

In this second example both products have same reference number (25) because both manufacturers are supplying the same strength and the dosage forms are considered similar as per explanation above.

**Disclaimer:**

The Global Fund does not endorse or warrant the fitness of any product on the List for a particular purpose, including in regard of its safety and/or efficacy in the treatment of HIV/AIDS, tuberculosis or malaria. In addition, the Global Fund assumes no responsibility for any misstatement or omission from the list and directs Principal Recipients of Global Fund grants to conduct their own independent confirmation that the information on a given product on the list is accurate before relying on it to make a purchase order for that product, and to ensure that any purchase is in compliance with all the requirements of the Global Fund's quality assurance policy. The Global Fund does not warrant or represent that the products listed have obtained regulatory approval for use of treatment of any disease in any particular country of the world, or that their use is otherwise in accordance with the national laws and regulations of any country, including, but not limited to, intellectual property laws. The Global Fund disclaims any and all liability and responsibility for any injury, death, damage or loss of any kind whatsoever that may arise as a result of, or in connection with the procurement, distribution and use of any product included in the list.

## List of A or B products:

**If there are two or more 'A' or ' B" products available, then the product must be procured from one of the A or B products.**
**Note: if the product intended for selection is not listed in this list , please refer to the List of ERP ( Expert Review Panel) Reviewed Products which are permitted for time limited procurement:**

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abacavir (ABC) | 20 mg / ml | Oral solution | ViiV HealthCare | A | Yes | Mississauga, Ontario | Canada | HDPE bottle | 240ml |
| | Abacavir (ABC) as sulfate | 20 mg / ml | Oral Solution | Cipla Ltd. | A -B | Yes | Cipla Limited, L-139 to L-146 Verna Goa | India | HDPE Bottle | 240ml, 100ml |
| | Abacavir (ABC) as sulfate | 20 mg / ml | Oral Solution | Meditabs Specialities Pvt Ltd | A | Yes | Satara, Maharastra | India | PET Bottle | 100ml |
| | Abacavir (ABC) as sulfate | 20 mg / ml | Oral Solution | Hetero labs limited | A | Yes | Unit III 22-110 Industrial development Area Jeedimetla, Hyderabad Andhra Pradesh, India | India | HDPE Bottle | 240ml |
| 2 | Abacavir (ABC) as sulfate | 60 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No 313 Bachyupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle; Blister | 60, 1000; 10 |
| | Abacavir (ABC) as sulfate | 60 mg | Dispersible Tablet | Cipla Ltd. | A -B | Yes | A-33, MIDC Patalganga | India | HDPE Bottle | 60 |
| | Abacavir (ABC) as sulfate | 60 mg | Tablet | Mylan Laboratories Ltd | A -B | Yes | Sinnar, Nashik, Maharashtra | India | HDPE | 60 |
| 3 | Abacavir (ABC) | 300 mg | Tablet | Cipla Ltd. | A - B | Yes | A-23, MIDC Patalganga | India | HDPE Bottle, | 60 |
| | Abacavir (ABC) | 300 mg | Tablet | ViiV HealthCare | A - B | Yes | Glaxo Operations UK, Ltd, Ware, Herthfordshire, UK; GSK, Poznan (packaging and release), Poland | UK | Blister | 60 |
| | Abacavir (ABC) | 300 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 60; 6*10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Abacavir (ABC) | 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle; Blister | 60; 6*10 |
| | Abacavir (ABC) as sulfate | 300 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle; Blister | 60; 6*10 |
| | Abacavir (ABC) | 300 mg | Tablet | Hetero labs limited | B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderabad -500 055 Andhra Pradesh, | India | HDPE Bottle; Blister Film Package | 60, 100, 500; 10 |
| | Abacavir (ABC) | 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No 313 Bachyupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle; | 60 ; |
| **4** | Abacavir + Lamivudine | 60 mg + 30 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 and 314, Bachupally Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle; Blister | 30, 60; 10*10 |
| | Abacavir (as Sulfate)+ Lamivudine | 60 mg + 30 mg | Tablet | Mylan Laboratories Ltd | A-B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle | 30, 60 |
| **5** | Abacavir Sulfate + Lamivudine | 60 mg + 30 mg | Tablets for oral suspension | Cipla Ltd. | A-B | Yes | A-33, MIDC Patalganga | India | HDPE container; Blister | 60, 120; 10 |
| | Abacavir Sulfate + Lamivudine | 60 mg + 30 mg | Tablets for oral suspension | Mylan Laboratories Ltd | B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **6** | Abacavir and Lamivudine Tablets for Oral Suspension | 120 mg / 60 mg | Tablets for Oral Suspension | Mylan Laboratories Ltd | B | Yes | Waluj, Aurangabad, Maharashtra, | India | HDPE bottle | 30, 2000 |
| **7** | Abacavir + Lamivudine | 600 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle; Blister | 30; 10 |
| | Abacavir + Lamivudine | 600 mg + 300 mg | Tablet Film coated | Glaxo SmithKline Ltd. | B | Yes | Berkeley, Greenford Middlesex | UK | HDPE Bottle | 30 |
| | Abacavir Sulfate+ Lamivudine | 600 mg + 300 mg | Tablet | Cipla Ltd. | B | Yes | A-33, MIDC Patalganga, | India | HDPE Bottle; Blister | 30; 3*10 |
| | Abacavir + Lamivudine | 600 mg + 300 mg | Tablet | Mylan Laboratories Ltd | B | -- | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30 |
| | Abacavir + Lamivudine | 600 mg + 300 mg | Tablet | Hetero labs limited | B | Yes | Hetero Labs Limited, Unit-V SEZ Unit I Survey No. 439, 440, 441 & 458 Mahaboob Nagar. | India | HDPE Bottle Blister | 30 10's x 10 |
| **8** | Abacavir (as Sulfate)+ Lamivudine + Zidovudine | 60 mg + 30 mg + 60 mg | Tablet | Mylan Laboratories Ltd | A | Yes | Sinnar,Nashik, Maharashtra | India | HDPE | 60 |
| **9** | Abacavir + Lamivudine + Zidovudine | 300 mg + 150 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle | 60 |
| | Abacavir + Lamivudine + Zidovudine | 300 mg + 150 mg + 300 mg | Tablet | ViiV HealthCare | A - B | Yes | Glaxo Operations UK, Ltd, Ware, Hertfordshire, UK; GSK, Poznan (packaging and release), Poland | UK | HDPE Botte Blister, | 60; 40; 60 |
| | Abacavir (as Sulfate)+ Lamivudine + Zidovudine | 300 mg + 150 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A-B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Abacavir + [Lamivudine + Zidovudine] | 300 mg + 150 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey 313 & 314, Bachupally, Quthubullapur Mandal, Hyderbad, Andhra Pradesh, | India | PVC / PVdC / Aluminum Foil | Blister Card Contains: 10 + 10 Each Carton Contains: 60 + 60 |
| **10** | Atazanavir | 50 mg / 1.5g | Oral powder | Bristol-Myers Squibb | B | Yes | Hounslow | UK | Bottle (HDPE) | 180g |
| **11** | Atazanavir | 100 mg | Hard Capsule | Bristol-Myers Squibb | B | Yes | Hounslow | UK | Bottle (HDPE) Blister (alu) | 60, 60 |
| | Atazanavir | 100 mg | Capsule | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle; | 60; |
| | Atazanavir | 100 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle Blister | 60,500 10 |
| **12** | Atazanavir | 150 mg | Capsule | Bristol-Myers Squibb | A | Yes | Evansville, Indianna, Mount Vernon, Indianna (primary packaging) | USA | HDPE bottle | 60 |
| | Atazanavir | 150 mg | Capsule Hard | Bristol-Myers Squibb | B | Yes | Hounslow | UK | Bottle (HDPE) Blister (alu) | 60 60 |
| | Atazanavir | 150 mg | Capsule | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle; | 60; |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Atazanavir ( as Sulfate) | 150 mg | Capsule | Mylan Laboratories Ltd | A -B | Yes | Sinnar, Nashik District, Maharashtra, India; Waluj, Aurangabad, Maharashtra, India | India | HDPE Bottle | 30, 100 |
| | Atazanavir ( as Sulfate) | 150 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle Blister | 60,180, 500 10 |
| **13** | Atazanavir | 200 mg | Capsule Hard | Bristol-Myers Squibb | B | Yes | Hounslow | UK | Bottle (HDPE) Blister (alu) | 60, 60 |
| | Atazanavir | 200 mg | Capsule | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle; | 60; |
| | Atazanavir | 200 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle Blister | 60,180, 500 10 |
| **14** | Atazanavir ( as Sulfate) | 300 mg | Capsule | Bristol-Myers Squibb | B | Yes | Evansville, Indiana, | USA | HDPE Bottle | 30 |
| | Atazanavir ( as Sulfate) | 300 mg | Capsule | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE Bottle | 30 |
| | Atazanavir ( as Sulfate) | 300 mg | Capsule | Mylan Laboratories Ltd | A- B | Yes | Sinnar, Nashik District, Maharashtra, India; Waluj, Aurangabad, Maharashtra, India | India | HDPE Bottle | 30, 100 |
| | Atazanavir ( as Sulfate) | 300 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle Blister | 30, 90,500 10 |
| **15** | Atazanavir+ Ritonavir | 300mg + 100mg | Tablet | Mylan Laboratories Ltd | A-B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 90, 120 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Atazanavir+Ritonavir | 300mg+100mg | Tablet (FDC) | Emcure Pharmaceuticals | B | Yes | Hinjwadi, Pune | India | HDPE Bottle | 30 |
| **16** | [Atazanavir Sulfate+ Ritonavir] +[Lamivudine and Zidovudine] | [300 mg / 100 mg] +[150 mg / 300 mg] | co-packaged Tablets | Mylan Laboratories Ltd | B | Yes | Sinnar, Nashik District 422 113, Maharashtra | India | PVC blister | Cartons containing 5 blister packs (consisting of PVC/Aclar film and coated aluminum foil), each containing two 1-day cards, for a 10 day supply. Three cartons are further packaged together for a 30 day supply |
| **17** | Darunavir (as ethanolate) | 75 mg | Tablets | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | A-B | Yes | Janssen Ortho LLC, Gurabo, Puerto Rico, United States (Manufacturing and release testing); Janssen-Cilag SpA, Latina, Italy (Testing and final QC release and packaging) | Puerto Rico | HDPE Bottle | 480 |
| **18** | Darunavir (as ethanolate) | 150 mg | Tablets | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | A-B | Yes | Janssen Ortho LLC, Gurabo, Puerto Rico, United States (Manufacturing and release testing); Janssen-Cilag SpA, Latina, Italy (Testing and final QC release and packaging) | Puerto Rico | HDPE Bottle | 240 |
| **19** | Darunavir | 400 mg | Tablets | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | B | Yes | Jansen Ortho LLc, Gurabo | Puerto Rico | HDPE Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Darunavir | 400mg | Tablet | Hetero Labs limited | B | Yes | UNIT-III, Hyderabad | India | HDPE Bottle | 60 |
| **20** | Darunavir | 600 mg | Tablets | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | B | Yes | Jansen Ortho LLc, Gurabo | Puerto Rico | HDPE Bottle | 60 |
| | Darunavir | 600 mg | Tablets | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | A | Yes | Janssen Ortho LLC, Gurabo, Puerto Rico, USA (manufacturing and release testing); Janssen-Cilag SpA, Latina, Italy (packaging, testing and QC release); Pharmacare Limited, Korsten, Port Elizabeth, South Africa (QC release) | USA | HDPE Bottle | 60 |
| | Darunavir | 600mg | Tablet | Hetero Labs limited | B | Yes | UNIT-III, Hyderabad | India | HDPE Bottle | 60 |
| **21** | Didanosine (ddI) | 2 g | Powder for Oral Solution | Bristol-Myers Squibb | A | Yes | Mount Vernon, Indiana, USA; Anagni (Secondary packaging and batch release), Italy | USA | Glass Bottle | 2g |
| **22** | Didanosine (ddI) | 10 mg / ml | Powder for Oral Solution | Bristol-Myers Squibb | B | Yes | Meymac Evansville, Indiana, | France USA | HDPE bottle | 2g |
| **23** | Didanosine (ddI) | 25 mg | Tablet | Bristol-Myers Squibb | A | Yes | Emcure, New jersy | USA | HDPE bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **24** | Didanosine (ddI) | 50 mg | Tablet | Bristol-Myers Squibb | A - B | Yes | Emcure, New jersy | USA | HDPE bottle | 60 |
| **25** | Didanosine (ddI) | 100 mg | Tablet | Bristol-Myers Squibb | A | Yes | Emcure, New jersy | USA | HDPE bottle | 60 |
| **26** | Didanosine (ddI) | 125 mg | Capsule Delayed release | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPPE Bottle | 30, 500 |
| | Didanosine (ddI) | 125 mg | Capsule Delayed release | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle Blister | 30, 500; 14 |
| **27** | Didanosine (ddI) | 150 mg | Tablet | Bristol-Myers Squibb | A - B | Yes | Emcure, New jersy | USA | HDPE bottle | 60 |
| **28** | Didanosine (ddI) | 200 mg | Capsule Delayed release | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle | 30, 500 |
| | Didanosine (ddI) | 200 mg | Capsule Delayed release | Barr Laboratories, Inc. | B | Yes | Pomona, NY | USA | Bottle | 30 |
| | Didanosine (ddI) | 200 mg | Capsule Delayed release | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle Blister | 30, 500; 10 |
| **29** | Didanosine (ddI) | 250 mg | Capsule Delayed release | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 500 |
| | Didanosine (ddI) | 250 mg | Capsule | Bristol-Myers Squibb | A | Yes | Mount Vernon, Indiana, USA; Anagni (Primary and secondary packaging and batch release), Italy | USA | Blister | 30 |
| | Didanosine (ddI) | 250 mg | Capsule Delayed release | Barr Laboratories, Inc. | B | Yes | Pomona, NY | USA | Bottle | 30 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Didanosine (ddI) | 250 mg | Capsule Delayed release | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle; Blister | 30, 500 10 |
| **30** | Didanosine (ddI) | 400 mg | Capsule Delayed release | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 500 |
| | Didanosine (ddI) | 400 mg | Capsule | Bristol-Myers Squibb | A | Yes | Mount Vernon, Indiana, USA; Anagni (Primary and secondary packaging and batch release), Italy | USA | Blister | 30 |
| | Didanosine (ddI) | 400 mg | Capsule Delayed release | Barr Laboratories, Inc. | B | Yes | Pomona, NY | USA | Bottle | 30 |
| | Didanosine (ddI) | 400 mg | Capsule Delayed release | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle; Blister | 30, 500; 5 |
| | Dolutegravir (as sodium salt) | 50mg | Tablets | ViiV Healthcare | A | Yes | Glaxo Operations UK Ltd, Hertfordshire (manufacturing and quality control), UK; Glaxo Wellcome S.A., Burgos (primary and secondary packaging, batch release), Spain | UK | Bottle | 30 |
| **31** | Efavirenz (EFV) | 30 mg / ml | Oral Solution | Merck Sharp & Dohme Limited | A - B | Yes | Patheon Inc. Mississauga, Ontario Harlem | Canada Netherlands | HDPE Bottle | 180ml |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **32** | Efavirenz (EFV) | 50 mg | Capsule | Merck Sharp & Dohme Limited | A | Yes | Manati, Harlem | Puerto Rico Netherlands | HDPE bottle | 30 |
| | Efavirenz (EFV) | 50 mg | Capsule | Microlabs Ltd | B | Yes | Verna, Goa | India | Bottle | 30, 60, 90 |
| | Efavirenz (EFV) | 50 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh<br>Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle; Blister | 30<br>10 |
| **33** | Efavirenz (EFV) | 50 mg | Tablet | Merck Sharp & Dohme Limited | A | Yes | South Granville, BN Haarlem (packager, responsible for batch release in the EU) | Australia | HDPE bottle | 30 |
| | Efavirenz (EFV) | 50 mg | Tablet | Mylan Laboratories Ltd | B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 90 |
| **34** | Efavirenz (EFV) | 100 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle; Blister | 30;<br>10 |
| **35** | Efavirenz (EFV) | 100mg | Tablet | Mylan Laboratories Ltd | B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 90 |
| | Efavirenz (EFV) | 100mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle; Blister | 30, 500;<br>10 |
| **36** | Efavirenz (EFV) | 100mg | Dispersible Tablet | Ranbaxy Laboratories Ltd | A | Yes | Mohali, Punjab | India | HDPE Bottle | 30 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **37** | Efavirenz (EFV) | 200 mg | Capsule | Cipla Ltd. | A - B | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE Bottle | 90, 1000 |
| | Efavirenz (EFV) | 200 mg | Capsule | Merck Sharp & Dohme Limited | A | Yes | Manati, Harlem | Puerto Rico Netherlands | HDPE bottle | 90 |
| | Efavirenz (EFV) | 200 mg | Capsule | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle; Blister | 90; 90 |
| | Efavirenz (EFV) | 200 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle; Blister | 30, 90; 10 |
| | Efavirenz (EFV) | 200 mg | Capsule | Microlabs Ltd | B | Yes | Verna, Goa | India | Bottle | 30,60,90 |
| **38** | Efavirenz (EFV) | 200 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 90 |
| | Efavirenz (EFV) | 200 mg | Tablet | Merck Sharp & Dohme Limited | A | Yes | South Granville, BN Haarlem (packager, responsible for batch release in the EU) | Australia | HDPE bottle | 90 |
| | Efavirenz (EFV) | 200 mg | Tablet | Mylan Laboratories Ltd | B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 90 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **39** | Efavirenz (EFV) | 600 mg | Tablet | Merck Sharp & Dohme Limited | A | Yes | Bristol-Myers Squibb Pharma, Manati, Puerto Rico; Merck Sharp & Dohme Australia Pty. Ltd, South Granville, Australia; Merck Sharp & Dohme, BV Haarlem, The Netherlands; Zhejiang Huahai Pharmaceutical Co., Ltd, Zhejiang, China | Puerto Rico Australia Netherlands China | HDPE bottle | 30 |
| | Efavirenz (EFV) | 600 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle Blister; | 30; 30 |
| | Efavirenz (EFV) | 600 mg | Tablet Film coated | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur Mandal, Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle; Blister | 30, 10 |
| | Efavirenz (EFV) | 600 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle; Blister | 30; 10 |
| | Efavirenz (EFV) | 600 mg | Tablet | Cipla Ltd. | A - B | Yes | L-139 to L-146, Verna Goa Quality Chemical Industries Ltd, Kampala | India Uganda | HDPE bottle Blister | 30, 500 10 |
| | Efavirenz (EFV) | 600 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 30 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Efavirenz (EFV) | 600 mg | Tablet Film coated | Hetero labs limited | A-B | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India; Unit-V, Mahaboob Nagar, Andhra Pradesh, India | India | HDPE Container | 30, 250 |
| | Efavirenz (EFV) | 600 mg | Tablet | Macleods Pharmaceutical | A-B | Yes | Himachal Pradesh | India | HDPE container | 30 |
| | Efavirenz (EFV) | 600 mg | Tablet | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle; Blister | 30, 60; 3*10 |
| | Efavirenz (EFV) | 600 mg | Tablet | Microlabs Ltd | B | Yes | Verna, Goa | India | HDPE bottle; Blister | 30,60,90 10 |
| | Efavirenz (EFV) | 600 mg | Tablet | Edict Pharmaceuticals Private Limited | B | Yes | Chennai | India | HDPE container | 30 |
| **40** | Efavirenz + [Lamivudine + Stavudine] | 600 mg + [150 mg + 30 mg] | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | Alu/Alu blister; Cardboard box | 2+1; 30+15 |
| **41** | Efavirenz + [Lamivudine + Zidovudine] | 600 mg + [150 mg + 300 mg] | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | PVC/PE/Aclar-Al foil ; Carton | 6 blisters per box Each blister has 5 x (2+1) |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Efavirenz + [Lamivudine + Zidovudine] | 600 mg + [150 mg + 300 mg] | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | Alu/Alu blister; Cardboard box | blister contains two lamivudine 150mg and zidovudine 300mg tablets and one efavirenz 600mg tablet. |
| | Efavirenz + [Lamivudine + Zidovudine] | 600 mg + [150 mg + 300 mg] | Tablet | Strides Arcolab Limited | B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 30 + (60) |
| | Efavirenz + [Lamivudine + Zidovudine] | 600 mg + [150 mg + 300 mg] | Co packed Tablet | Mylan Laboratories Ltd | | | Sinnar, Nashik District 422 113, Maharashtra | India | Blister cards. | 10-day supply (5 two-day blister cards consisting of PVC/PvDC film and coated aluminum foil) |
| **42** | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Merck Sharp & Dohme Limited | A | Yes | Patheon Inc. Mississauga, Ontario MSD BV Haarlem ( packaging and batch release site) | Canada | HDPE bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir Disoproxil Fumarate | 600 mg + 200 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A-B | Yes | Sinnar,Nashik, Maharashtra, Waluj, Aurangabad, Maharashtra, Dhar, Madhya Pradesh | India | HDPE bottle | 30, 100 |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Cipla Ltd. | A | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE Bottle | 30 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle | 30, 100 |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Hetero labs limited | A-B | Yes | Hetero Labs Limited, Unit-V SEZ Unit I Survey No. 439, 440, 441 & 458 Mahaboob Nagar. | India | HDPE | Bottles 30's and 500's, |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Shasun Pharmaceuticals Ltd, Periyakalapet, Pondicherry, India | India | HDPE Bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Macleods Pharmaceuticals Limited | A-B | Yes | Kachigam, Damam | India | HDPE Bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Strides Arcolab Limited | A | Yes | Anekal Taluk, Bangalore, India | India | HDPE Bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir | 600 mg + 200 mg + 300 mg | Tablet | Emcure Pharmaceuticals Limited | B | Yes | Plot No. P-1 & P-2, I.T.-B.T. Park, Phase II, MIDC, Hinjwadi, PUNE | India | HDPE Bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir Disoproxil | 600 mg+200 mg+300 mg | Tablet | Bristol-Myers Squibb and Gilead Sciences Ltd | B | Yes | Carrigtohill, County Cork | Ireland | HDPE Bottle | 30 |
| | Efavirenz + Emtricitabine + Tenofovir Disoproxil | 600 mg+200 mg+300 mg | Tablet | Gilead Sciences Ltd | B | Yes | Patheon Inc. Mississauga, Ontario | Canada | HDPE Bottle | 30 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **43** | Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate | 600 mg + 300 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A- B | Yes | Sinnar,Nashik, Maharashtra; H-12 & H-13, M.I.D.C, Waluj, Aurangabad Maharastra | India | HDPE Bottle | 30, 100 |
| | Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate | 600 mg + 300 mg + 300 mg | Tablet | Hetero labs limited | B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderaba | India | HDPE Bottle | 30 |
| | Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate | 600 mg + 300 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Aurobindo Pharma Limited Unit-VII (SEZ) Mahaboob Nagar (Dt) AP | India | HDPE Bottle | 30, 500 |
| | Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate | 600 mg + 300 mg + 300 mg | Tablet | Cipla Ltd. | B | Yes | UNIT-II-Patalganga | India | HDPE Bottle | 30 |
| | Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate | 600 mg + 300 mg + 300 mg | Tablet | Macleods Pharmaceuticals Limited | B | Yes | Macleods Pharmaceuticals Limited Baddi, District Solan, Himachal Pradesh | India | HDPE Bottle | 30 |
| **44** | Emtricitabine | 10 mg/ml | oral solution | Gilead Sciences | B | Yes | Country Cork | Ireland | Bottle | 170ml |
| **45** | Emtricitabine | 200 mg | Capsule | Cipla Ltd. | A - B | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE Bottle | 30, 1000 |
| | Emtricitabine | 200 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE Bottle, Blister | 30, 500 10 |
| | Emtricitabine | 200 mg | Capsule | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 30, 100; 2*10, 3*10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Emtricitabine | 200 mg | Capsule | Gilead Sciences, Inc. | B | Yes | Foster City | USA | HDPE Bottle, | 30 |
| **46** | (Emtricitabine + Nevirapine) +Tenofovir | (200+200)+300 | Tablets co-packed | Mylan Laboratories Ltd | A | Yes | Sinnar,Nashik, Maharashtra | India | Alu/Alu blister | (1+2) per blister, 3 blisters in a carton |
| **47** | Emtricitabine + Tenofovir | 200 mg + 245 mg | Tablet Film coated | Gilead Sciences, Inc. | B | Yes | Granta Park Abington, Cambridge | UK | Bottle (HDPE) | 30 |
| | Emtricitabine + Tenofovir | 200 mg + 300 mg | Tablet | Gilead Sciences, Inc. | A | Yes | Altana Pharma, Oranienburg GmbH, Patheon Inc. Mississauga, Ontario Aspen Pharmacare, Port Elizabeth, | Germany Canada South Africa | HDPE bottle | 30 |
| | Emtricitabine + Tenofovir disoproxil fumarate | 200 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle | 30 |
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle; blister | 30,100; 10 |
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Cipla Ltd. | A-B | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE Bottle | 30 |
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Hetero labs limited | A-B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderaba | India | HDPE bottle | 30, 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 30 |
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Macleods Pharmaceuticals Limited | A | Yes | Kachigam, Daman, | India | HDPE bottleAlu/Alu blister | 30; 10 x 10 |
| | Emtricitabine + Tenofovir Disoproxil Fumarate | 200 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Shasun Pharmaceuticals Limited, Periyakalapet, Puducherry, India | India | HDPE bottle | 30 |
| **48** | [Emtricitabine + Tenofovir Disoproxil Fumarate]+Nevirapine | 200 mg /300 mg co-packaged with 200 mg | Co packed Tablet | Mylan Laboratories Ltd | B | Yes | Sinnar, Nashik District 422 113, Maharashtra | India | Blister cards. | Cartons containing 5 blister packs (consisting of aluminum-aluminum blisters), each containing two 1-day cards, for a 10 day supply. Three cartons are further packaged together for a 30 day supply |
| | [Emtricitabine + Tenofovir Disoproxil Fumarate]+Nevirapine | 200 mg /300 mg co-packaged with 200 mg | Co packed Tablet | Macleods Pharmaceuticals Limited | A | Yes | Kachigam, Daman, | India | Alu/Alu blister | (1 + 2) combipack |
| **49** | Enfuvirtide | 90mg/ml | Injection | Hoffmann-La Roche Inc. | B | Yes | Basle | Switzerland | Vials | 60+60 vials of water for inj+syringe |
| **50** | Etravirine | 25mg | Tablet | Janssen-Cilag International NV, Belgium | A-B | Yes | Janssen-Cilag SpA, Latina, Italy | Italy | HDPE Bottle | 120 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **51** | Etravirine | 100mg | Tablet | Janssen Infectious Diseases - Diagnostics BVBA/ Pharmacare South Africa | A-B | Yes | Borgo San Michele, Latina Janssen-Cilag SpA, Latina, Italy (Manufacturing, packaging, release testing and final QC release) | Italy | HDPE Bottle | 120 |
| **52** | Etravirine | 200mg | Tablet | Janssen-Cilag International NV, Belgium | A-B | Yes | Janssen-Cilag SpA, Latina, Italy | Italy | HDPE Bottle | 60 |
| **53** | Fosamprenavir (FPV) | 700 mg | Tablet | Glaxo SmithKline Ltd. | B | Yes | Glaxo Wellcome Operations | UK | HDPE bottle | 60 |
| **54** | Indinavir (IDV) | 200 mg | Capsule Hard | Merck Sharp & Dohme Limited | B | Yes | Hertford Road, Hertfordshire | UK | HDPE Bottle | 180,270, 360 |
| **55** | Indinavir (IDV) | 400 mg | Capsule | Hetero Labs Limited | A | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India | India | Al/Al strip; HDPE bottle | 10; 180 |
| **56** | Indinavir (IDV) | 400 mg | Capsule | Merck Sharp & Dohme Limited | A | Yes | Elkton, Virgina | USA | HDPE bottle | 180 |
| | Indinavir (IDV) | 400 mg | Capsule Hard | Merck Sharp & Dohme Limited | B | Yes | Hertford Road, Hertfordshire | UK | Bottle (HDPE) | 18, 90, 180 |
| | Indinavir (IDV) as Sulfate | 400 mg | Capsule | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Container | 90, 180 |
| **57** | Lamivudine (3TC) | 10 mg / ml | Oral Solution | ViiV HealthCare | A | Yes | Mississauga, Ontario | Canada | HDPE bottle | 240ml |
| | Lamivudine (3TC) | 10 mg / ml | Oral Solution | Cipla Ltd. | A - B | Yes | Cipla Limited L-139 to L-146, Verna Goa, Indore, SEZ, Pithampur, Dist Dhar (M.P.) | India | PET bottle; HDPE bottle | 100ml; 240ml |
| | Lamivudine (3TC) | 10 mg / ml | Oral Solution | Hetero labs limited | B | Yes | Unit-III 22-110, Industrial Development Area Jeedimetla, Hyderabad | India | HDPE Bottle | 240ml |
| | Lamivudine (3TC) | 10 mg / ml | Oral Solution | Macleods Pharmaceutical | A | Yes | Solan, Himachal Pradesh, India | India | HDPE Bottle | 240ml |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **58** | Lamivudine (3TC) | 30mg | Tablet | Cipla Ltd. | A | Yes | Goa | India | HDPE Bottle | 60 |
| | Lamivudine (3TC) | 30mg | Tablet | Microlabs Ltd | A | Yes | Verna, Goa | India | PVC/PVdC/ Alu blister ; HDPE bottle | 10 60,100,500 ,1000 |
| | Lamivudine (3TC) | 30mg | Disp Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle | 60 |
| **59** | Lamivudine (3TC) | 100 mg | Tablet Film coated | Glaxo SmithKline Ltd. | B | Yes | Ware, Hartfordshire | UK | Blister; Bottle | 28, 84 |
| **60** | Lamivudine (3TC) | 150 mg | Tablet Film Coated | Macleods Pharmaceutical | A - B | Yes | Kachigam, Daman Baddi, H.P. | India | HDPE Bottle; Blister | 60; 6*10 |
| | Lamivudine (3TC) | 150 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle; Blister | 30, 60; 10 |
| | Lamivudine (3TC) | 150 mg | Tablet | Aspen Pharmacare Ltd. | A | Yes | Port Elizabeth, Korsten | South Africa | Metallised lay flat pack, PP bottle | 60 |
| | Lamivudine (3TC) | 150 mg | Tablet | Cipla Ltd. | A | Yes | Goa; Meditab Specialities Ltd, Goa | India | HDPE Bottle | 30, 60 |
| | Lamivudine (3TC) | 150 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur Mandal, Hyderabad, Andhra Pradesh, Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle; Blister | 60; 10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine (3TC) | 150 mg | Tablet Film coated | ViiV HealthCare | A - B | Yes | Glaxo Operations UK, Ltd, Ware, Hertfordshire, UK; GSK, Poznan (packaging and release), Poland Pharmacare (ASPEN), Port Elizabeth, | UK South Africa | HDPE bottle | 60 |
| | Lamivudine (3TC) | 150 mg | Tablet | Hetero labs limited | A-B | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India; STADA-VN Joint Venture Co, Ltd, Duong Province, Vietnam | India Vietnam | HDPE Bottle Blister, | 60, 600 10; |
| | Lamivudine (3TC) | 150 mg | Tablet Film Coated | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 60; 10 |
| | Lamivudine (3TC) | 150 mg | Tablet | Ranbaxy Laboratories Ltd | A - B | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle, Blister | 60, 10 |
| | Lamivudine (3TC) | 150 mg | Tablet | Alkem Laboratories Ltd | B | Yes | Amaliya, Daman | India | HDPE Bottle | 60 |
| | Lamivudine (3TC) | 150 mg | Tablet | Microlabs Ltd | B | Yes | Verna, Goa | India | HDPE bottle Blister | 30, 60, 90 10 |
| **61** | Lamivudine (3TC) | 300 mg | Tablet | Mylan Laboratories Ltd | A -B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 60; 6*10 |
| | Lamivudine (3TC) | 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur Mandal, Hyderabad, Andhra Pradesh, | India | HDPE Bottle; Blister | 30; 10 |
| | Lamivudine (3TC) | 300 mg | Tablet | Cipla Ltd. | A | Yes | Goa | India | HDPE Bottle | 30,60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine (3TC) | 300 mg | Film coated Tablet | Strides Arcolab Limited | B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle, | 30; 60 |
| | Lamivudine (3TC) | 300 mg | Tablet | Macleods Pharmaceutical | A - B | Yes | Kachigam, Daman | India | HDPE Bottle; Blister | 30; 3* 10; 6*10 |
| | Lamivudine (3TC) | 300 mg | Tablet | Glaxo SmithKline Ltd. | B | Yes | Greenford, Middlesex | UK | High density polyethylene (HDPE) bottle | 30 |
| | Lamivudine (3TC) | 300 mg | Tablet | Hetero labs limited | B | Yes | Unit III 22-110, I.D.A., Jeedimetla Jeedimeta, Hyderabad | India | HDPE bottle | 30, 600 |
| | Lamivudine (3TC) | 300 mg | Tablet | Microlabs Ltd | B | Yes | Verna, Goa | India | HDPE bottle Blister | 30, 60, 90 10 |
| **62** | Lamivudine + Nevirapine + Stavudine | 30 mg + 50 mg + 6 mg | Dispersible Tablet | Cipla Ltd. | A - B | Yes | Plot No. L-139, L146-Verna, Goa | India | HDPE bottle | 60, 1000 |
| **63** | Lamivudine + Nevirapine + Stavudine | 60 mg + 100 mg + 12 mg | Dispersible Tablet | Cipla Ltd. | A - B | Yes | Plot No. L-139, L146-Verna, Goa | India | HDPE Bottle | 60, 1000 |
| **64** | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Cipla Ltd. | A - B | Yes | Kurkumbh India , Patalganga, India; Plot 136,146(UNITIII&IV), L147,L147-1 UNIT-VII-Goa,; Himachal Pradesh, India; Cipla Ltd Indore, SEZ, Pithampur, Dist Dhar (M.P.), India | India | HDPE bottle | 30; 60; 1000 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Hetero labs limited | A-B | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India; Unit-V, Mahaboob Nagar, Andhra Pradesh, India | India | HDPE Bottle | 60, 100, 500 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Mylan Laboratories Ltd | A | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle, Blister | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Varichem Pharmaceuticals | A | Yes | Harare | Zimbabwe | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Macleods Pharmaceutical | B | Yes | Kachigam, Daman | India | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Strides Arcolab Limited | B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Stavudine | 150 mg +200 mg+ 30 mg | Tablet | Pharmacare Ltd. | B | Yes | Strides Ltd, Banglore | India | HDPE Bottle | 60 |
| **65** | Lamivudine + Nevirapine + Zidovudine | 30mg+ 50mg +60mg | Dispersible Tablet | Mylan Laboratories Ltd | A -B | Yes | Sinnar, Nashik District, Maharashtra, India; Waluj, Aurangabad, Maharashtra, India | India | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Zidovudine | 30mg+ 50mg +60mg | Tablet for Oral Suspension | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli, Indlavadi cross, Anekal Taluk, Bangalore | India | HDPE Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Nevirapine + Zidovudine | 30mg+ 50mg +60mg | Tablet for Oral Suspension | Cipla Ltd. | B | Yes | Plot No. L-147, L147-1 (Unit VII), Verna Industrial Estate, Verna Salcette Goa, 403 722, India | India | HDPE Bottle | 60, 1000 |
| **66** | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | India; Waluj, Aurangabad, Maharashtra, India; Mission Vivacare Limited, Pithampur, Dhar, M.P., India; Shasun Pharmaceutical Ltd, Periyakalapet, Puducherry, India | India | HDPE bottle ; PVC/PVdC/ Alu blister; | 60; 6 X 10; |
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Cipla Ltd. | A - B | Yes | Cipla Ltd, Goa,UNIT-III & UNIT-IV India; Cipla Ltd, Indore, SEZ, Pithampur, Dist Dhar (M.P.), India; Quality Chemical Industries Ltd, Kampala, Uganda; Cipla Ltd Baddi, Himachal Pradesh, India | India Uganda | HDPE bottle | 30, 60, 500 |
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Hetero labs limited | A-B | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India; Unit-V, Mahaboob Nagar, Andhra Pradesh, India | India | Blister; HDPE bottle | 10; 60, 100, 500 |
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle /PVdc/PVC blister | 60, 10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Macleods Pharmaceutical | A-B | Yes | Kachigam, Daman Baddi, H.P. | India | HDPE Bottle | 60 |
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle; Blister | 60; 10 |
| | Lamivudine + Nevirapine + Zidovudine | 150 mg + 200 mg + 300 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 60 |
| **67** | Lamivudine + Stavudine | 30 mg + 6mg | Tablet for Oral Suspension | Cipla Ltd. | A - B | Yes | L-139 to L-146, UNIT-III & VI, Verna Goa | India | HDPE bottle; Blister | 30, 60, 1000; 14 |
| **68** | Lamivudine + Stavudine | 60 mg + 12mg | Tablet for Oral Suspension | Cipla Ltd. | A - B | Yes | L-139 to L-146, UNIT-III & VI, Verna Goa | India | HDPE bottle; Blister | 30, 60, 1000; 14 |
| **69** | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Cipla Ltd. | A - B | Yes | Patalganga, L-139 to L-146, UNIT-III & VI, Verna Goa | India | HDPE bottle | 60, 30, 1000 |
| | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle Blister; | 60 10; |
| | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Strides Arcolab Limited | A | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Macleods Pharmaceutical | B | Yes | Kachigam, Daman | India | HDPE Bottle | 60 |
| | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Hetero labs limited | B | Yes | Unit III 22-110, I.D.A., Jeedimetla Jeedimeta, Hyderabad | India | HDPE Bottle | 30, 60, 100, 500 |
| | Lamivudine + Stavudine | 150 mg + 30 mg | Tablet | Pharmacare Ltd. | B | Yes | Strides Ltd, Banglore | India | HDPE Bottle | 60 |
| **70** | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Hetero labs limited | A-B | Yes | Unit-III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad | India | HDPE Bottle | 30, 60, 100, 500 |
| | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A-B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle | 30, 100 |
| | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle | 30 |
| | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Cipla Ltd. | A- B | Yes | D-7 MIDC Kurkumbh; Quality Chemical Industries Ltd, Kampala, Uganda | India | HDPE Bottle<br>Blister | 30, 500<br>10 |
| | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A-B | Yes | Shasun Pharmaceuticals Ltd | India | HDPE Bottle | 30 |
| | Lamivudine + Tenofovir disoproxil fumarate | 300 mg + 300 mg | Tablet | Macleods Pharmaceutical | A-B | Yes | Kachigam- Daman<br>Baddi- Himachal Pradesh | India | HDPE Bottle<br>Blister | 30<br>10 |
| **71** | [Lamivudine+Tenofovir] +Atazanavir+ Ritonavir | [300mg+300mg] +300mg+100mg | Capsules+ Tablets+ Tablets | Mylan Laboratories Ltd | A | Yes | Sinnar,Nashik, Maharashtra, | India | Alu/Alu Blister per co packed blister | (1+1+1) per coblister; 3 blisters in a carton |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **72** | [Lamivudine+Tenofovir] +Nevirapine | [300mg + 300mg] +200mg | Tablets ( co-packaged) | Mylan Laboratories Ltd | A- B | Yes | Sinnar,Nashik, Maharashtra Village Theda, Post Office Lodhimajra | India | Alu/Alu Blister; Blister in Carton | (1+2) per blister; 3 blisters in a carton |
| | [Lamivudine+Tenofovir disoproxil fumarate] + Nevirapine | (300+300mg) + 200mg | Co-Blistered tablets | Aurobindo | B | Yes | Aurobindo Pharma Limited, Unit VII (SEZ) Andhra Pradesh | India | Blister | 1 Blister contains(4 +2) 15 blisters in a box. |
| | [Lamivudine+Tenofovir disoproxil fumarate] + Nevirapine | (300+300mg) + 200mg | Co-Blistered tablets | Hetero labs limited | B | Yes | Hetero Labs Limited Unit III 22-110, I D A, Jeedimetla, Hyderabad | India | Co Blister | 1 Blister contains(1 +2) 10 blisters in a box. |
| | [Lamivudine+Tenofovir disoproxil fumarate] + Nevirapine | (300+300mg) + 200mg | Co-Blistered tablets | Macleods Pharmaceutical | A | Yes | Kachigam, Damam | India | Alu/Alu blister | one carton contains one blister of one lamivudine /TDF tablet and one blister of two nevirapine tablets |
| **73** | Lamivudine + Zidovudine | 30 mg + 60 mg | Dispersible Tablet | Mylan Laboratories Ltd | A -B | Yes | Sinnar-Nashik, Maharashtra Waluj, Aurangabad | India | HDPE | 60 |
| | Lamivudine + Zidovudine | 30 mg + 60 mg | Dispersible Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle | 60 |
| | Lamivudine + Zidovudine | 30 mg + 60 mg | Tablet for Oral Suspension | Cipla Ltd. | B | Yes | Unit VII, Verna, Goa. | India | HDPE bottle; Blister | 60 |
| **74** | Lamivudine + Zidovudine | 30 mg + 60 mg | Tablet | Mylan Laboratories Ltd | A -B | Yes | Sinnar-Nashik, Maharashtra Waluj, Aurangabad | India | HDPE | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Zidovudine | 30 mg + 60 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | UNIT III, Survey No. 313 and 314, Bachupally Quthubullapur Mandal, Hyderabad, Andhra Pradesh | India | HDPE Bottle; Blister | 60, 1000; 10 |
| | Lamivudine + Zidovudine | 30 mg + 60 mg | Tablet | Cipla Ltd. | B | Yes | L-139 to L-146, UNIT III-Verna Goa, | India | HDPE bottle; Blister | 60; 1000 10 |
| | Lamivudine + Zidovudine | 30 mg + 60 mg | Tablet | Micro labs | A | Yes | Verna, Goa | India | PVC/PVdC/ Alu blister HDPE | 6 x 10; 60, 100, 1000 |
| **75** | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey, Hyderabad, Andhra Pradesh Unit-VII (SEZ), Andhra Pradesh | India | HDPE bottle; Blister | 60; 10 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Cipla Ltd. | A - B | Yes | Plot No. L-147, L147-1, Verna Goa, Indore, SEZ, Pithampur, Dist Dhar (M.P.), India; Quality Chemical Industries Ltd, Kampala, Uganda; Cipla Ltd Baddi, Himachal Pradesh, India Meditab Specialities Pvt Ltd, Kundaim, Goa, India | India Uganda | HDPE bottle ; Blister | 60, 1000 ; 10, 14 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Hetero Labs Limited | A-B | Yes | Unit-III, 22-110, Jeedimetla, Hyderabad Unit-V, Hyderabad | India | HDPE bottle Blister; | 60, 500 10; |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle ; Blister | 60; 10 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | ViiV HealthCare | A | Yes | Glaxo Operations UK, Ltd, Ware, Hertfordshire, UK; GSK, Poznan (packaging and release), Poland | UK | Bottle Blister, | 60, 60 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle; Alu/PA/PVC Blister; PVdC/PVC blister | 60; 10 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Varichem Pharmaceuticals | A | Yes | Harare | Zimbabwe | HDPE Bottle | 60 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Film coated Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 60 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Universal Corporation | A | Yes | Kikuyu | Kenya | HDPE | 60 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Microlabs Ltd | A | Yes | Verna, Goa | India | HDPE bottle; PVDC/PVC/ Alu blister; | 30, 60, 90; 10*10; |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Pharmacare Ltd. | B | Yes | Port Elizabeth, Korsten | South Africa | Blister | 60 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Macleods Pharmaceutical | A -B | Yes | Kachigam, Daman Baddi, H.P. | India | HDPE Bottle; Blister | 60; 6*10, 12*10 |
| | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE bottle Blister | 60 10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **76** | [Lamivudine + Zidovudine] + Nevirapine | [150mg+300mg]+ 200mg | Co packaged Tablet | Hetero labs limited | B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderabad | India | PVC/Alu Blister; Blister | 10 doses on one blister sheet and 6 sheets included in the carton |
| | [Lamivudine + Zidovudine] + Nevirapine | [150mg+300mg]+ 200mg | Co packaged Tablet | Pharmacare Ltd. | B | Yes | Fairclough Road, Korsten, Port Elizabeth, 6020, | South Africa | Blister cards. | Each card contains 6 lamivudine / zidovudine tablets and 6 nevirapine tablets. |
| | [Lamivudine + Zidovudine] + Nevirapine | [150mg+300mg]+ 200mg | Co packaged Tablet | Strides Arcolab Limited | B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle | (60)+60 |
| **77** | Lopinavir (LPV) + Ritonavir (RTV) | (80 mg + 20 mg) / ml | Oral Solution | Abbott Laboratories Ltd. | A -B | Yes | Queensborough, Kent, | UK | PET bottle | 60ml, 160ml |
| | Lopinavir (LPV) + Ritonavir (RTV) | (80 mg + 20 mg) / ml | Oral Solution | Abbott Laboratories Ltd. | B | Yes | North Chicago | Illinois,USA | PET bottle | 160ml |
| | Lopinavir (LPV) + Ritonavir (RTV) | (80 mg + 20 mg) / ml | Oral Solution | Cipla Ltd. | B | Yes | Plot No. L-139, S-103 & M-62, Verna Industrial Estate, Verna Salcette, Goa, | India | Amber coloured PET Bottle | 160ml |
| **78** | Lopinavir (LPV) + Ritonavir (RTV) | 100 mg + 25 mg | Tablet | Abbott Laboratories Ltd. | A | Yes | Ludwigshafen | Germany | HDPE bottle | 60 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 100 mg + 25 mg | Tablet | Abbott Laboratories Ltd. | B | Yes | North Chicago | Illinois,USA | HDPE bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Lopinavir (LPV) + Ritonavir (RTV) | 100 mg + 25 mg | Tablet | Mylan Laboratories Ltd | A | Yes | Unit-8, Andhra Pradesh (for premix), India Sinnar, Nashik District, Maharashtra (for tablets), India | India | HDPE Bottle | 120 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 100 mg + 25 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313 and 314 Bachupally Quthubullapur Mandal, Hyderabad Andhra Pradesh | India | HDPE Bottle; Blister | 60; 6*10 |
| **79** | Lopinavir (LPV) + Ritonavir (RTV) | 133.3 mg + 33.3 mg | Capsule | Abbott Laboratories Ltd. | A | Yes | RP Scherer, Florida, | USA | HDPE bottle | 90 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 133.3 mg + 33.3 mg | Capsule Soft | Abbott Laboratories Ltd. | B | Yes | Queenborough, Kent | UK | Bottle (HDPE) Bottle (PVC) | 90, 180 |
| **80** | Lopinavir (LPV) + Ritonavir (RTV) | 200 mg + 50 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 120; 6. 12 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 200 mg + 50 mg | Tablet | Abbott Laboratories Ltd. | A | Yes | Ludwigshafen, | Germany | HDPE bottle | 120 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 200 mg + 50 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313 and 314 Bachupally Quthubullapur Mandal, Hyderabad Andhra Pradesh | India | HDPE Bottle; Blister | 120; 6*10 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 200 mg + 50 mg | Tablet | Cipla Ltd. | B | Yes | A-42, MIDC Patalganga | India | HDPE Bottle Blister | 120, 10 |
| | Lopinavir (LPV) + Ritonavir (RTV) | 200 mg + 50 mg | Tablet | Hetero labs limited | A-B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderabad | India | HDPE Alu/Alu Blister Alu/PVC/PVdC blister | 60, 120 10 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **81** | Nevirapine (NVP) | 10 mg / ml | Oral Suspension | Boehringer Ingelheim | A | Yes | Roxane, Columbus, | USA | HDPE bottle+ syringe | 240ml + 5ml |
| | Nevirapine (NVP) | 10 mg / ml | Oral Suspension | Cipla Ltd. | A | Yes | Cipla Ltd, Goa, India; Meditab Specialties Pvt Ltd, Maharashtra, India; Indore, SEZ, Pithampur, Dist Dhar (M.P.), India | India | Amber coloured PET Bottle Amber coloured glass bottle | 100ml, 240 25ml, 10ml |
| **82** | Nevirapine | 20mg | Tablet | MicroLabs | A | Yes | Plot No: S-155 to S-159, Phase III, Verna Industrial Estate, Verna, Goa-403722 | India | HDPE bottle Blister | 30,60,90 10 |
| **83** | Nevirapine (NVP) | 50mg | Tablet for Oral Suspension | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313 and 314 Bachupally Quthubullapur Mandal, Hyderabad Andhra Pradesh | India | HDPE bottle | 30, 180 |
| | Nevirapine (NVP) | 50mg | Tablet for Oral Suspension | Cipla Ltd. | A-B | Yes | A-42, MIDC, Patalganga, | India | HDPE bottle Blister | 60, 1000 10 |
| | Nevirapine (NVP) | 50mg | Dispersible tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh, | India | HDPE bottle | 60 |
| | Nevirapine | 50mg | Tablet | MicroLabs | A | Yes | Plot No: S-155 to S-159, Phase III, Verna Industrial Estate, Verna, Goa-403722 | India | HDPE bottle Blister | 30,60,90 10 |
| **84** | Nevirapine (NVP) | 100mg | Tablet for Oral Suspension | Cipla Ltd. | A-B | Yes | A-42, MIDC, Patalganga, | India | HDPE bottle Blister | 60, 1000 10 |
| | Nevirapine (NVP) | 100mg | Dispersible tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh, | India | HDPE bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Nevirapine | 100mg | Tablet | MicroLabs | A | Yes | Plot No: S-155 to S-159, Phase III, Verna Industrial Estate, Verna, Goa-403722 | India | HDPE bottle<br>Blister | 30,60,90<br>10 |
| **85** | Nevirapine (NVP) | 200 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur Mandal, Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle; Blister | 60; 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Cipla Ltd. | A - B | Yes | Plot 136,146(UNITIII&IV), L147,L147-1 UNIT-VII-Goa; Meditab Specialties Pvt Ltd, Kundaim, Goa, Quality Chemical Industries Ltd, Kampala, Uganda | India Uganda | HDPE Bottle; Blister | 60, 1000 ; 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Hetero labs limited | A-B | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India | India | HDPE bottle Blister; | 60, 100,500, 1000 10; |
| | Nevirapine (NVP) | 200 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle; Blister | 60; 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Ranbaxy Laboratories Ltd | A - B | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE bottle ; Blister | 60, 1000; 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Container | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Nevirapine (NVP) | 200 mg | Tablet | Aspen Pharmacare Ltd. | A | Yes | Port Elizabeth, Korsten | South Africa | Blister | 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Boehringer Ingelheim | A | Yes | Boehringer Ingelheim Pharma GmbH & Co, KG, Ingelheim, Germany; Boehringer Ingelheim Ellas A.E., Koropi, Greece | Germany Greece | Blister | 60 |
| | Nevirapine (NVP) | 200 mg | Tablet | Macleods Pharmaceutical | A- B | Yes | Kachigam, Daman | India | HDPE bottle; PVdC/PVC/ Alu Blister | 60; 6*10, 12*10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Emcure Pharmaceuticals Limited | B | Yes | Hinjwadi, Pune | India | HDPE Bottle; Blister | 60; 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | Huahai Pharmaceutical | B | Yes | Xunqiao, Linhai, Zhejiang | China | HDPE Bottle | 60 |
| | Nevirapine (NVP) | 200 mg | Tablet | Microlabs Ltd | A-B | Yes | Verna, Goa | India | HDPE Blister | 60 10 |
| | Nevirapine (NVP) | 200 mg | Tablet | ScieGen Pharmaceuticals | B | Yes | | USA | HDPE Bottle | 30, 500 |
| **86** | Raltegravir | 400mg | Tablet | Merck & Co, USA | B | Yes | Elkton Zhejiang Huahai Singapore | USA China Singapore | Bottle | 60 |
| | Raltegravir | 400mg | Tablet | Hetero labs limited | B | Yes | Unit III 22 - 110, Industrial development Area, Jeedimetla, Hyderabad | India | Bottle Blister | 60, 120 10'sx10 10'sx14 |
| **87** | Raltegravir | 100mg | Chewable tablet | Merck & Co, USA | B | Yes | Elkton Zhejiang Huahai | USA China | Bottle | 60 |
| **88** | Raltegravir | 25mg | Chewable tablet | Merck & Co, USA | B | Yes | Elkton Zhejiang Huahai | USA China | Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **89** | Ritonavir (RTV) | 80 mg / ml | Oral Solution | Abbott Laboratories Ltd. | A | Yes | Queenborough, Kent | UK | PET bottle | 90ml |
| **90** | Ritonavir (RTV) | 25 mg | Tablet | Cipla | B | Yes | A-42, MIDC, Patalganga, | India | HDPE Bottle | 60 |
| **91** | Ritonavir (RTV) | 50 mg | Tablet | Cipla | B | Yes | A-42, MIDC, Patalganga, | India | HDPE Bottle | 60 |
| **92** | Ritonavir (RTV) | 100 mg | Capsule | Abbott Laboratories Ltd. | A | Yes | RP Scherer, Florida, Beinheim | USA France | HDPE bottle; | 84, |
| | Ritonavir (RTV) | 100 mg | Tablet | Mylan Laboratories Ltd | A | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 30, 120 |
| | Ritonavir (RTV) | 100 mg | Tablet | Abbott Laboratories Ltd. | A | Yes | Luwigshafen, | Germany | HDPE Bottle | 30, 60 |
| | Ritonavir (RTV) | 100 mg | Tablet | Cipla | B | Yes | A-42, MIDC, Patalganga, | India | HDPE Bottle | 30 |
| **93** | Saquinavir | 200mg | Capsule | F.Hoffman-La Roche | A | Yes | RP Scherer, Baden; Basel | Germany; Switzerland | HDPE bottle | 180; 270 |
| **94** | Saquinavir | 500mg | Tablet | F.Hoffman-La Roche | A | Yes | Madrid | Spain | HDPE Bottle | 120 |
| **95** | Stavudine (d4T) | 1 mg / ml | Powder for Oral Solution | Bristol-Myers Squibb | A | Yes | Evansville, Indiana, | USA | HDPE bottle | 200ml |
| | Stavudine (d4T) | 1 mg / ml | Powder for Oral Solution | Bristol-Myers Squibb | B | Yes | Meymac | France | HDPE Container | 200ml |
| | Stavudine (d4T) | 1 mg / ml | Powder for Oral Solution | Cipla Ltd. | A -B | Yes | M-61, M-62, M-63, Verna Goa | India | HDPE bottle | 200ml |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **96** | Stavudine (d4T) | 15 mg | Capsule | Bristol-Myers Squibb | A | Yes | Emcure Pharmaceuticals USA, New Jersey (manufacturing and primary packaging), USA. Bristol-Myers Squibb, Anagni (Frosinone) (secondary packaging, testing and batch release), Italy. | USA | HDPE bottle Blister | 60 14 |
| | Stavudine (d4T) | 15 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle | 60 |
| | Stavudine (d4T) | 15 mg | Capsule | Hetero labs limited | B | Yes | Unit-III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad | India | HDPE Bottle | 60, 100, 1000 |
| **97** | Stavudine (d4T) | 20 mg | Capsule | Aspen Pharmacare Ltd. | A | Yes | Port Elizabeth, Korsten | South Africa | Glass bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Stavudine (d4T) | 20 mg | Capsule | Bristol-Myers Squibb | A | Yes | Emcure Pharmaceuticals USA, New Jersey (manufacturing and primary packaging), USA. Bristol-Myers Squibb, Anagni (Frosinone) (secondary packaging, testing and batch release), Italy. | USA | HDPE bottle Blister | 60 14 |
| | Stavudine (d4T) | 20 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle | 60 |
| | Stavudine (d4T) | 20 mg | Capsule | Hetero labs limited | B | Yes | Unit-III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad | India | HDPE Bottle | 60, 100, 1000 |
| **98** | Stavudine (d4T) | 30 mg | Capsule | Aspen Pharmacare Ltd. | A | Yes | Port Elizabeth, Korsten | South Africa | Glass bottle | 60 |
| | Stavudine (d4T) | 30 mg | Capsule | Ranbaxy Laboratories Ltd | A | Yes | Paonta Sahib, Himachal Pradesh | India | HDPE Bottle; Blister | 60; 60 |
| | Stavudine (d4T) | 30 mg | Capsule | Macleods Pharmaceutical | A | Yes | Kachigam, Daman | India | HDPE Bottle | 60 |
| | Stavudine (d4T) | 30 mg | Capsule | Aurobindo Pharma Ltd | B | Yes | Unit III, Survey No. 313 &314 Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh | India | HDPE bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Stavudine (d4T) | 30 mg | Capsule | Bristol-Myers Squibb | A - B | Yes | Emcure Pharmaceuticals USA, New Jersey (manufacturing and primary packaging), USA. Bristol-Myers Squibb, Anagni (Frosinone) (secondary packaging, testing and batch release), Italy. | USA | HDPE bottle Blister | 60 14 |
| | Stavudine (d4T) | 30 mg | Capsule | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 60; 10 |
| | Stavudine (d4T) | 30 mg | Capsule | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE bottle | 60 |
| | Stavudine (d4T) | 30 mg | Capsule | Hetero labs limited | B | Yes | Unit-III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad | India | HDPE Bottle | 60, 100, 500 |
| **99** | Tenofovir Disoproxil Fumarate | 40mg/gm( Eq to 33mg/gm of Tenofovir Disoproxil | granule | Gilead Sciences | B | Yes | Takeda GmbH Country Cork | Germany Ireland | HDPE bottle | 60g |
| **100** | Tenofovir Disoproxil Fumarate | 300mg | Tablet Film coated | Gilead Sciences, Inc. | B | Yes | Patheon Inc. Mississauga, Ontario Nycomed Oranienburg GmbH, | Canada Germany | HDPE container | 30 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Cipla Ltd. | A - B | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE bottle | 30, 1000 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Gilead Sciences, Inc. | A | Yes | Patheon Inc., Mississauga,Ontario, Canada; Altana Pharma, Oranienburg GmbH, Oranienburg, Germany; Aspen Pharmacare, OSD Facility, Korsten, Port Elizabeth, South Africa | Germany Canada South Africa | HDPE bottle | 30 |
| | Tenofovir Disoproxil Fumarate | 300mg | Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Shahib, Himachal Pradesh | India | HDPE Bottle | 30 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Gilead Sciences, Inc. | B | Yes | Granta Park Abington, Cambridge | UK | HDPE bottle Blister | 30 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle; Blister | 30,100; 2*10 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Strides Arcolab Limited | A-B | Yes | 36/7, Suragajakkanahalli Indlavadi cross Anekal Taluk Bangalore | India | HDPE Bottle Blister | 30 10 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Aurobindo Pharma Ltd | B | Yes | Unit - III Survey No. 313 & 314, Bachupally, Quthubullapur Mandal Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle | 30, |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Hetero labs limited | A-B | Yes | Unit III 22-110 Industrial development Area Jeedimetla, Hyderabad | India | HDPE Bottle | 30, 60, 100, 500, 1000 |
| | Tenofovir Disoproxil Fumarate | 300 mg | Tablet | Macleods Pharmaceutical | A | Yes | Kachigam, Daman Baddi, H.P. | India | HDPE bottle | 30, |
| **101** | Zidovudine | 60mg | Tablet | Aurobindo Pharma Ltd | B | Yes | UNIT- III,Survey No. 313 and 314, Bachupally Quthubullapur Mandal, Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE Bottle;<br><br>Blister | 60, 1000;<br><br>10 |
| | Zidovudine | 60mg | Tablet | Microlabs Ltd | A | Yes | Verna, Goa | India | PVC/PVdC/ Alu blister HDPE bottle | 10x10 60, 100, 500, 1000 |
| **102** | Zidovudine | 60mg | Dispersible Tablet | Ranbaxy Laboratories Ltd | A | Yes | Paonta Shahib, Himachal Pradesh | India | HDPE Bottle | 60 |
| **103** | Zidovudine | 10mg/ml | Infusion solution | ViiV HealthCare | A | Yes | Barnard Castle, County Durham | UK | Glass vial | 20ml |
| **104** | Zidovudine | 50mg/5ml | Oral solution | ViiV HealthCare | A | Yes | Mississauga, Ontario, | Canada | PET bottle | 200ml |
| | Zidovudine | 50mg/5ml | Oral solution | Combino Pharm S.L. | A | Yes | Medea, Barcelona | Spain | PET bottle+10ml syringe | 200ml + 10ml sy |
| | Zidovudine | 50mg/5ml | Oral solution | Hetero labs limited | A | Yes | Unit-III, Jeedimetla, Hyderabad, Andhra Pradesh, India | India | HDPE Bottle | 240ml |
| | Zidovudine | 50mg/5ml | Oral solution | Cipla Ltd. | A - B | Yes | Cipla Limited L-139 to L-146, Verna Goa, Meditab Specialities Ltd | India | HDPE bottle; PET Bottle | 100ml, 240ml 100ml; |
| | Zidovudine | 50mg/5ml | Oral solution | Meditab Speciliaties Ltd | A | Yes | Maharastra | India | PET Bottle | 100ml |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Zidovudine | 50mg/5ml | Oral solution | Macleods Pharmaceutical | A | Yes | Solan, Himachal Pradesh, India | India | HDPE Bottle | 240ml |
| | Zidovudine | 50mg/5ml | Oral solution | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur Mandal, Hyderabad, Andhra Pradesh | India | HDPE bottle, with dose delivery device | 240ml |
| **105** | Zidovudine | 100mg | Tablet | Mylan Laboratories Ltd | A - B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE Bottle | 60 |
| **106** | Zidovudine | 100mg | Capsules | Cipla Ltd. | A - B | Yes | L138-147 L150 s103-105 VernaGoa; Indore, SEZ, Pithampur, District Dhar (M.P.), India | India | HDPE Bottle | 100; 1000 |
| | Zidovudine | 100mg | Capsules | Combino Pharm S.L. | A | Yes | Medea, Barcelona, | Spain | Al Strip | 100 |
| | Zidovudine | 100mg | Capsules | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No 313 and 314, Bachupally Quthubullapur Mandal Hyderabad, Anda Pradesh<br>Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle;<br>Blister | 100<br>10 |
| | Zidovudine | 100mg | Capsules | ViiV HealthCare | A | Yes | S.C. Europharm, Brasov, | Romania | Bottle<br>Blister | 100;<br>100 |
| **107** | Zidovudine | 250mg | Capsules | ViiV HealthCare | A | Yes | S. C. Europharm, Brasov | , Romania | Blister | 40 |
| | Zidovudine | 250mg | Capsules | Combino Pharm S.L. | A | Yes | Medea, Barcelona, | Spain | HDPE bottle; Blister | 40, 300 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| **108** | Zidovudine | 300mg | Tablets | Aurobindo Pharma Ltd | B | Yes | Unit III Survey No. 313, Bachupally, Quthubullapur, Hyderabad, Andhra Pradesh Unit-VII (SEZ), Mahaboob Nagar (DT), Andhra Pradesh | India | HDPE bottle; Blister | 60; 10 |
| | Zidovudine | 300mg | Tablets | Hetero labs limited | A-B | Yes | Unit-III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad | India | HDPE bottle | 60, 500, 600 |
| | Zidovudine | 300mg | Tablets | ViiV HealthCare | A | Yes | Glaxo Operations UK, Ltd, Ware, Hertfordshire, UK; Glaxo Wellcome SA, Aranda (packaging and release), Spain | UK | Bottle Blister | 28 28, 60; |
| | Zidovudine | 300mg | Tablets | Ranbaxy Laboratories Ltd | A -B | Yes | Paonta Sahib, Himachal Pradesh, | India | HDPE bottle; Blister | 60; 10, 8 |
| | Zidovudine | 300mg | Tablets | Mylan Laboratories Ltd | A -B | Yes | Sinnar,Nashik, Maharashtra | India | HDPE bottle; Blister | 60; 2 x 10 |
| | Zidovudine | 300mg | Capsules | Combino Pharm S.L. | A | Yes | Medea, Barcelona, | Spain | Blister ; HDPE bottle | 60, 300 |
| | Zidovudine | 300mg | Tablets | Cipla Ltd. | A - B | Yes | Plot No. L-147, L147-1, Verna Goa, | India | HDPE Bottle; Blister | 30, 60, 1000 ; 10 |
| | Zidovudine | 300mg | Tablets | HEC Pharma | B | Yes | Sunshine Lake Pharma Co. Ltd, GuangDong | China | HDPE Bottle | 60 |

| Ref.No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | WHO Prequalification/ SRA | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| | Zidovudine | 300mg | Tablets | Microlabs Ltd | A | yes | Verna, Goa | India | PVDC/PVC/ Alu blister; HDPE bottle | 10; 30, 60, 90 |
| | Zidovudine | 300mg | Tablets | Macleods Pharmaceutical | A | yes | Kachigam, Daman | India | PVDC/PVC/ Alu blister; HDPE bottle | 10; 60 |

**End of A or B products List**

The Global Fund
To Fight AIDS, Tuberculosis and Malaria

## List of ERP ( Expert Review Panel) Reviewed Products which are permitted for time limited procurement:

If there is no or only one A or B product available ( supply of the product cannot be done within 90 days after the receipt of the Purchase Order by the manufacturer) , grant funds may be used to procure a ERP reviewed product eligible for procurement for limited time (12 months) period. The PR must send the "notification form" (available at http://www.theglobalfund.org/en/procurement/quality/?lang=en) to the Global Fund and upon receiving the " No Objection" letter form the Global Fund, the procurement can proceed. Please note that the QC test of the selected ERP product will be performed by the Global Fund.

| Ref. No | International Non-proprietary name | Strength/ Dose | Dosage form | Supplier/ Manufacturer(s) | Global Fund QA Standard | Period Validity for ERP Review | Manufacturing site | Country | Material | Pack |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Darunavir Ethanolate | 400mg | Tablet | Cipla | ERP Reviewed | 30/11/2015 | (Unit II), MIDC, Patalganga, | India | HDPE Bottle | 60 |
| 2 | Darunavir Ethanolate | 600mg | Tablet | Cipla | ERP Reviewed | 30/11/2015 | (Unit II), MIDC, Patalganga, | India | HDPE Bottle | 60 |
| 3 | Lopinavir+Ritonavir | 40mg/10mg | Pellets in Capsule | Cipla | ERP Reviewed | 01/03/2016 | Plot L147 to L-147-1, Verna Industrial Estate, Verna, Goa | India | HDPE Bottle | 120 |
| 4 | Lopinavir/Ritonavir | 100/25mg | Tablet | Macleods | ERP Reviewed | 30/11/2015 | Block No.: 2, Village Theda Baddi,Solan, Himachal Pradesh | India | HDPE Bottle | 30 |

**End of ERP Reviewed products list**